トップ > 製品検索結果一覧
| クリップ | Code No. | 品名 | データ | ||||
|---|---|---|---|---|---|---|---|
| データ
シート |
項目 | 標識 | MHC Allele | 包装 | 価格 | 在庫 | |
| 配列 | 位置 | 温度 | |||||
|
|
|||||||
|
TB-M107-2 |
HLA-A*02:01 PAP 299-307 Tetramer-ALDVYNGLL-APC |
|
||||
| cancer | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALDVYNGLL | 299-307 | 4°C | |||||
|
|
TB-M107-1 |
HLA-A*02:01 PAP 299-307 Tetramer-ALDVYNGLL-PE |
|
||||
| cancer | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALDVYNGLL | 299-307 | 4°C | |||||
|
|
TS-M095-2 |
HLA-A*02:01 PP2A Tetramer-SLLPAIVEL-APC |
|
||||
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SLLPAIVEL | 402-410 | 4°C | |||||
|
|
TS-M095-1 |
HLA-A*02:01 PP2A Tetramer-SLLPAIVEL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SLLPAIVEL | 402-410 | 4°C | |||||
|
|
TS-M117-2 |
HLA-A*02:01 PRAME100-108 Tetramer-VLDGLDVLL-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| VLDGLDVLL | 100-108 | 4°C | |||||
|
|
TS-M117-1 |
HLA-A*02:01 PRAME100-108 Tetramer-VLDGLDVLL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| VLDGLDVLL | 100-108 | 4°C | |||||
|
|
TS-M119-2 |
HLA-A*02:01 PRAME142-151 Tetramer-SLYSFPEPEA-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SLYSFPEPEA | 142-151 | 4°C | |||||
|
|
TS-M119-1 |
HLA-A*02:01 PRAME142-151 Tetramer-SLYSFPEPEA-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SLYSFPEPEA | 142-151 | 4°C | |||||
|
|
TS-M116-2 |
HLA-A*02:01 PRAME300-309 Tetramer-ALYVDSLFFL-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| ALYVDSLFFL | 300-309 | 4°C | |||||
|
|
TS-M116-1 |
HLA-A*02:01 PRAME300-309 Tetramer-ALYVDSLFFL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| ALYVDSLFFL | 300-309 | 4°C | |||||
|
|
TS-M118-2 |
HLA-A*02:01 PRAME425-433 Tetramer-SLLQHLIGL-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| SLLQHLIGL | 425-433 | 4°C | |||||
|
|
TS-M118-1 |
HLA-A*02:01 PRAME425-433 Tetramer-SLLQHLIGL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| SLLQHLIGL | 425-433 | 4°C | |||||
|
|
TS-M087-2 |
HLA-A*02:01 PSA Tetramer-KLQCVDLHV-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| KLQCVDLHV | 146-154 | 4°C | |||||
|
|
TS-M087-1 |
HLA-A*02:01 PSA Tetramer-KLQCVDLHV-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| KLQCVDLHV | 146-154 | 4°C | |||||
|
|
TB-M120-2 |
HLA-A*02:01 PSA141-150 Tetramer-FLTPKKLQCV-APC |
|
||||
| cancer | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| FLTPKKLQCV | 141-150 | 4°C | |||||
|
|
TS-M104-2 |
HLA-A*02:01 RHAMM Tetramer-ILSLELMKL-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| ILSLELMKL | 165-173 | 4°C | |||||
|
|
TS-M104-1 |
HLA-A*02:01 RHAMM Tetramer-ILSLELMKL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| ILSLELMKL | 165-173 | 4°C | |||||
|
|
TS-M096-2 |
HLA-A*02:01 RNA-dependent helicase Tetramer-YLLPAIVHI-APC |
|
||||
|
|
Others | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| YLLPAIVHI | 148-156 | 4°C | |||||
|
|
TS-M096-1 |
HLA-A*02:01 RNA-dependent helicase Tetramer-YLLPAIVHI-PE |
|
||||
|
|
Others | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| YLLPAIVHI | 148-156 | 4°C | |||||
|
|
TB-0175-M |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Monomer-KLPDDFTGCV |
|
||||
| virus | Unlabeled | A*02:01 | 50 µg | ￥190,000 |
0 (お問合せ） |
||
| KLPDDFTGCV | -80°C | ||||||
|
|
TB-0174-M |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Monomer-RLNEVAKNL |
|
||||
| virus | A*02:01 | 50 µg | ￥190,000 |
0 (お問合せ） |
|||
| RLNEVAKNL | -80°C | ||||||
|
|
TB-0177-M |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Monomer-RLQSLQTYV |
|
||||
| virus | A*02:01 | 50 µg | ￥190,000 |
0 (お問合せ） |
|||
| RLQSLQTYV | -80°C | ||||||
|
|
TB-0176-M |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Monomer-YLQPRTFLL |
|
||||
| virus | A*02:01 | 50 µg | ￥190,000 |
0 (お問合せ） |
|||
| YLQPRTFLL | -80°C | ||||||
|
|
TB-0175-2 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-KLPDDFTGCV-APC |
|
||||
| virus | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLPDDFTGCV | 4°C | ||||||
|
|
TB-0175-4 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-KLPDDFTGCV-BV421 |
|
||||
| virus | BV421 | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLPDDFTGCV | 4°C | ||||||
|
|
TB-0175-1 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-KLPDDFTGCV-PE |
|
||||
| virus | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLPDDFTGCV | 4°C | ||||||
|
|
TB-0174-2 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLNEVAKNL-APC |
|
||||
| virus | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLNEVAKNL | 4°C | ||||||
|
|
TB-0174-4 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLNEVAKNL-BV421 |
|
||||
| virus | BV421 | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLNEVAKNL | 4°C | ||||||
|
|
TB-0174-1 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLNEVAKNL-PE |
|
||||
| virus | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLNEVAKNL | 4°C | ||||||
|
|
TB-0177-2 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLQSLQTYV-APC |
|
||||
| virus | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLQSLQTYV | 4°C | ||||||
|
|
TB-0177-4 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLQSLQTYV-BV421 |
|
||||
| virus | BV421 | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLQSLQTYV | 4°C | ||||||
|
|
TB-0177-1 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-RLQSLQTYV-PE |
|
||||
| virus | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLQSLQTYV | 4°C | ||||||
|
|
TB-0176-2 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-YLQPRTFLL-APC |
|
||||
| virus | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| YLQPRTFLL | 4°C | ||||||
|
|
TB-0176-4 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-YLQPRTFLL-BV421 |
|
||||
| virus | BV421 | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| YLQPRTFLL | 4°C | ||||||
|
|
TB-0176-1 |
HLA-A*02:01 SARS-CoV-2 Spike Glycoprotein Tetramer-YLQPRTFLL-PE |
|
||||
| virus | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| YLQPRTFLL | 4°C | ||||||
|
|
TS-M079-2 |
HLA-A*02:01 SSX-2 Tetramer-KASEKIFYV-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| KASEKIFYV | 41-49 | 4°C | |||||
|
|
TS-M079-1 |
HLA-A*02:01 SSX-2 Tetramer-KASEKIFYV-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| KASEKIFYV | 41-49 | 4°C | |||||
|
|
TS-M085-2 |
HLA-A*02:01 Survivin (T2M) Tetramer-LMLGEFLKL-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| LMLGEFLKL | 96-104 | 4°C | |||||
|
|
TS-M085-1 |
HLA-A*02:01 Survivin (T2M) Tetramer-LMLGEFLKL-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| LMLGEFLKL | 96-104 | 4°C | |||||
|
|
TB-0155-2 |
HLA-A*02:01 Survivin Tetramer-LTLGEFLKL-APC |
|
||||
| cancer | APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| LTLGEFLKL | 96-104 | 4°C | |||||
|
|
TB-0155-4 |
HLA-A*02:01 Survivin Tetramer-LTLGEFLKL-BV421 |
|
||||
| cancer | BV421 | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| LTLGEFLKL | 96-104 | 4°C | |||||
|
|
TB-0155-1 |
HLA-A*02:01 Survivin Tetramer-LTLGEFLKL-PE |
|
||||
| cancer | PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| LTLGEFLKL | 96-104 | 4°C | |||||
|
|
TB-M122-2 |
HLA-A*02:01 VZV IE62 Tetramer-ALWALPHAA-APC |
|
||||
|
virus VSV |
APC | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALWALPHAA | 593-601 | 4°C | |||||
|
|
TB-M122-1 |
HLA-A*02:01 VZV IE62 Tetramer-ALWALPHAA-PE |
|
||||
|
virus VSV |
PE | A*02:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALWALPHAA | 593-601 | 4°C | |||||
|
|
TS-M140-2 |
HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-APC |
|
||||
|
|
cancer | APC | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| VLDFAPPGA | 37-45 | 4°C | |||||
|
|
TS-M140-1 |
HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-PE |
|
||||
|
|
cancer | PE | A*02:01 | 50 tests | ￥209,000 | 1-9 | |
| VLDFAPPGA | 37-45 | 4°C | |||||
|
|
TS-M100-2 |
HLA-A*03:01 CMV IE1 184-192 Tetramer-KLGGALQAK-APC |
|
||||
|
|
virus | APC | A*03:01 | 50 tests | ￥209,000 | 1-9 | |
| KLGGALQAK | 184-192 | 4°C | |||||
|
|
TS-M100-1 |
HLA-A*03:01 CMV IE1 184-192 Tetramer-KLGGALQAK-PE |
|
||||
|
|
virus | PE | A*03:01 | 50 tests | ￥209,000 | 1-9 | |
| KLGGALQAK | 184-192 | 4°C | |||||
|
|
TS-M124-2 |
HLA-A*03:01 EBV BRLF1 Tetramer-RVRAYTYSK-APC |
|
||||
|
|
virus | APC | A*03:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| RVRAYTYSK | 148-156 | 4°C | |||||
|
|
TS-M124-1 |
HLA-A*03:01 EBV BRLF1 Tetramer-RVRAYTYSK-PE |
|
||||
|
|
virus | PE | A*03:01 | 50 tests | ￥209,000 | 1-9 | |
| RVRAYTYSK | 148-156 | 4°C | |||||
|
|
TS-M033-2 |
HLA-A*03:01 EBV EBNA3A 603-611 Tetramer-RLRAEAQVK-APC |
|
||||
|
|
virus | APC | A*03:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| RLRAEAQVK | 603-611 | 4°C | |||||
|
|
TS-M033-1 |
HLA-A*03:01 EBV EBNA3A 603-611 Tetramer-RLRAEAQVK-PE |
|
||||
|
|
virus | PE | A*03:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| RLRAEAQVK | 603-611 | 4°C | |||||
|
|
TB-0166-2 |
HLA-A*03:01 gp100 Tetramer-ALLAVGATK-APC |
|
||||
| cancer | APC | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALLAVGATK | 4°C | ||||||
|
|
TB-0166-4 |
HLA-A*03:01 gp100 Tetramer-ALLAVGATK-BV421 |
|
||||
| cancer | BV421 | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALLAVGATK | 4°C | ||||||
|
|
TB-0166-1 |
HLA-A*03:01 gp100 Tetramer-ALLAVGATK-PE |
|
||||
| cancer | PE | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ALLAVGATK | 4°C | ||||||
|
|
TB-0109-2 |
HLA-A*03:01 HIV p17 gag Tetramer-RLRPGGKKK-APC |
|
||||
|
virus HIV |
APC | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLRPGGKKK | 4°C | ||||||
|
|
TB-0109-4 |
HLA-A*03:01 HIV p17 gag Tetramer-RLRPGGKKK-BV421 |
|
||||
|
virus HIV |
BV421 | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLRPGGKKK | 4°C | ||||||
|
|
TB-0109-1 |
HLA-A*03:01 HIV p17 gag Tetramer-RLRPGGKKK-PE |
|
||||
|
virus HIV |
PE | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RLRPGGKKK | 4°C | ||||||
|
|
TB-0105-2 |
HLA-A*03:01 hTERT Tetramer-KLFGVLRLK-APC |
|
||||
| cancer | APC | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLFGVLRLK | 4°C | ||||||
|
|
TB-0105-4 |
HLA-A*03:01 hTERT Tetramer-KLFGVLRLK-BV421 |
|
||||
| cancer | BV421 | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLFGVLRLK | 4°C | ||||||
|
|
TB-0105-1 |
HLA-A*03:01 hTERT Tetramer-KLFGVLRLK-PE |
|
||||
| cancer | PE | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| KLFGVLRLK | 4°C | ||||||
|
|
TB-0103-2 |
HLA-A*03:01 Influenza NP Tetramer-ILRGSVAHK-APC |
|
||||
|
virus Influenza |
APC | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ILRGSVAHK | 4°C | ||||||
|
|
TB-0103-4 |
HLA-A*03:01 Influenza NP Tetramer-ILRGSVAHK-BV421 |
|
||||
|
virus Influenza |
BV421 | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ILRGSVAHK | 4°C | ||||||
|
|
TB-0103-1 |
HLA-A*03:01 Influenza NP Tetramer-ILRGSVAHK-PE |
|
||||
|
virus Influenza |
PE | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| ILRGSVAHK | 4°C | ||||||
|
|
TB-0108-2 |
HLA-A*03:01 Survivin 18-27 (modK) Tetramer-RISTFKNWPK-APC |
|
||||
| cancer | APC | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RISTFKNWPK | 4°C | ||||||
|
|
TB-0108-4 |
HLA-A*03:01 Survivin 18-27 (modK) Tetramer-RISTFKNWPK-BV421 |
|
||||
| cancer | BV421 | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RISTFKNWPK | 4°C | ||||||
|
|
TB-0108-1 |
HLA-A*03:01 Survivin 18-27 (modK) Tetramer-RISTFKNWPK-PE |
|
||||
| cancer | PE | A*03:01 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| RISTFKNWPK | 4°C | ||||||
|
|
TS-M135-2 |
HLA-A*11:01 EBV LMP2 S9T Tetramer-SSCSSCPLTK-APC |
|
||||
|
|
virus | APC | A*11:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SSCSSCPLTK | 340-349 | 4°C | |||||
|
|
TS-M135-1 |
HLA-A*11:01 EBV LMP2 S9T Tetramer-SSCSSCPLTK-PE |
|
||||
|
|
virus | PE | A*11:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SSCSSCPLTK | 340-349 | 4°C | |||||
|
|
TS-M111-2 |
HLA-A*11:01 EBV LMP2 Tetramer-SSCSSCPLSK-APC |
|
||||
|
|
virus | APC | A*11:01 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SSCSSCPLSK | 340-349 | 4°C | |||||
|
|
TS-M111-1 |
HLA-A*11:01 EBV LMP2 Tetramer-SSCSSCPLSK-PE |
|
||||
|
|
virus | PE | A*11:01 | 50 tests | ￥209,000 | 1-9 | |
| SSCSSCPLSK | 340-349 | 4°C | |||||
|
|
TS-M141-2 |
HLA-A*24:02 ACC-1 Tetramer-DYLQYVLQI-APC |
|
||||
|
|
cancer | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| DYLQYVLQI | 15-23 | 4°C | |||||
|
|
TS-M141-1 |
HLA-A*24:02 ACC-1 Tetramer-DYLQYVLQI-PE |
|
||||
|
|
cancer | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| DYLQYVLQI | 15-23 | 4°C | |||||
|
|
TS-M062-2 |
HLA-A*24:02 Adenovirus 11 Hexon37-45 Tetramer-TYFNLGNKF-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYFNLGNKF | 37-45 | 4°C | |||||
|
|
TS-M062-1 |
HLA-A*24:02 Adenovirus 11 Hexon37-45 Tetramer-TYFNLGNKF-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYFNLGNKF | 37-45 | 4°C | |||||
|
|
TS-M064-2 |
HLA-A*24:02 Adenovirus 11 Hexon696-704 Tetramer-VYSGSIPYL-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| VYSGSIPYL | 696-704 | 4°C | |||||
|
|
TS-M064-1 |
HLA-A*24:02 Adenovirus 11 Hexon696-704 Tetramer-VYSGSIPYL-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| VYSGSIPYL | 696-704 | 4°C | |||||
|
|
TS-M063-2 |
HLA-A*24:02 Adenovirus 5 Hexon37-45 Tetramer-TYFSLNNKF-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYFSLNNKF | 37-45 | 4°C | |||||
|
|
TS-M063-1 |
HLA-A*24:02 Adenovirus 5 Hexon37-45 Tetramer-TYFSLNNKF-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYFSLNNKF | 37-45 | 4°C | |||||
|
|
TS-M112-2 |
HLA-A*24:02 CA9219-227 Tetramer-EYRALQLHL-APC |
|
||||
|
|
cancer | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| EYRALQLHL | 219-227 | 4°C | |||||
|
|
TS-M112-1 |
HLA-A*24:02 CA9219-227 Tetramer-EYRALQLHL-PE |
|
||||
|
|
cancer | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| EYRALQLHL | 219-227 | 4°C | |||||
|
|
TB-0117-4 |
HLA-A*24:02 EBV LMP-2 Tetramer-TYGPVFMCL-BV421 |
|
||||
|
virus EBV |
BV421 | A*24:02 | 50 tests | ￥190,000 |
0 (お問合せ） |
||
| TYGPVFMCL | 4°C | ||||||
|
|
TS-M035-2 |
HLA-A*24:02 EBV LMP2 C8S Tetramer-TYGPVFMSL-APC |
|
||||
|
|
virus EBV |
APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYGPVFMSL | 419-427 | 4°C | |||||
|
|
TS-M035-1 |
HLA-A*24:02 EBV LMP2 C8S Tetramer-TYGPVFMSL-PE |
|
||||
|
|
virus EBV |
PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| TYGPVFMSL | 419-427 | 4°C | |||||
|
|
TS-M034-2 |
HLA-A*24:02 EBV LMP2 Tetramer-PYLFWLAAI-APC |
|
||||
|
|
virus EBV |
APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| PYLFWLAAI | 131-139 | 4°C | |||||
|
|
TS-M034-1 |
HLA-A*24:02 EBV LMP2 Tetramer-PYLFWLAAI-PE |
|
||||
|
|
virus EBV |
PE | A*24:02 | 50 tests | ￥209,000 | 1-9 | |
| PYLFWLAAI | 131-139 | 4°C | |||||
|
|
TS-M089-2 |
HLA-A*24:02 gp100-intron 4 Tetramer-VYFFLPDHL-APC |
|
||||
|
|
cancer | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| VYFFLPDHL | 170-178 | 4°C | |||||
|
|
TS-M089-1 |
HLA-A*24:02 gp100-intron 4 Tetramer-VYFFLPDHL-PE |
|
||||
|
|
cancer | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| VYFFLPDHL | 170-178 | 4°C | |||||
|
|
TS-M044-2 |
HLA-A*24:02 HCV E2 717-725 Tetramer-EYVLLLFLL-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| EYVLLLFLL | 717-725 | 4°C | |||||
|
|
TS-M044-1 |
HLA-A*24:02 HCV E2 717-725 Tetramer-EYVLLLFLL-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| EYVLLLFLL | 717-725 | 4°C | |||||
|
|
TS-M164-2 |
HLA-A*24:02 HHV-6B U54 Tetramer-PFHCSFHTI-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| PFHCSFHTI | 267-275 | 4°C | |||||
|
|
TS-M164-1 |
HLA-A*24:02 HHV-6B U54 Tetramer-PFHCSFHTI-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| PFHCSFHTI | 267-275 | 4°C | |||||
|
|
TS-M110-2 |
HLA-A*24:02 HIV nef 134-141 Tetramer-RYPLTFGW-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| RYPLTFGW | 134-141 | 4°C | |||||
|
|
TS-M110-1 |
HLA-A*24:02 HIV nef 134-141 Tetramer-RYPLTFGW-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| RYPLTFGW | 134-141 | 4°C | |||||
|
|
TS-M049-2 |
HLA-A*24:02 HPV16 E6 Tetramer-VYDFAFRDL-APC |
|
||||
|
|
virus | APC | A*24:02 | 50 tests | ￥209,000 | 1-9 | |
| VYDFAFRDL | 49-57 | 4°C | |||||
|
|
TS-M049-1 |
HLA-A*24:02 HPV16 E6 Tetramer-VYDFAFRDL-PE |
|
||||
|
|
virus | PE | A*24:02 | 50 tests | ￥209,000 | 1-9 | |
| VYDFAFRDL | 49-57 | 4°C | |||||
|
|
TS-M144-2 |
HLA-A*24:02 Influenza PA130-138 Tetramer-YYLEKANKI-APC |
|
||||
|
|
virus Influenza |
APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| YYLEKANKI | 130-138 | 4°C | |||||
|
|
TS-M144-1 |
HLA-A*24:02 Influenza PA130-138 Tetramer-YYLEKANKI-PE |
|
||||
|
|
virus Influenza |
PE | A*24:02 | 50 tests | ￥209,000 | 1-9 | |
| YYLEKANKI | 130-138 | 4°C | |||||
|
|
TS-M145-2 |
HLA-A*24:02 Influenza PB1216-224 Tetramer-SYLIRALTL-APC |
|
||||
|
|
virus Influenza |
APC | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SYLIRALTL | 216-224 | 4°C | |||||
|
|
TS-M145-1 |
HLA-A*24:02 Influenza PB1216-224 Tetramer-SYLIRALTL-PE |
|
||||
|
|
virus Influenza |
PE | A*24:02 | 50 tests | ￥209,000 |
0 (お問合せ） |
|
| SYLIRALTL | 216-224 | 4°C | |||||
※在庫につきましては2024年05月20日 00時05分時点における在庫数を表示してあります。
※価格の赤色表示につきましては、
キャンペーン価格の表示となっております。
※このサイトからは直接注文はできません。ご注意ください。
※保存温度の表記について： RT: 室温
※本サイトの掲載製品は、品質改良のため予告なく仕様などの変更、または販売中止となる場合がございます。あらかじめご了承ください。